Cross-Sector entity

Dr. Jay Mei

Person
7

ATG-201 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each.

2 verified stories tracked

Last mentioned: Mar 4, 2026

RSS updates
Share

Entity pulse

Recent coverage · Dr. Jay Mei

2 stories
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Dr. Jay Mei

ATG-201 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each. Dr. Jay Mei appears in 2 tracked Cross-Sector stories from March 4, 2026.

Stories tracked
2
Sources per story
2

Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Dr. Jay Mei. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Clinical Filings Target

    Antengene plans to submit CTAs for ATG-201 in China and Australia by the end of Q1 2026.

  2. Investor Briefings

    Antengene hosts conference calls in Chinese and English to discuss the UCB partnership.

  3. Global License Agreement

    Antengene and UCB announce exclusive worldwide licensing deal for ATG-201.

  4. Regulatory Filings

    Planned submission of clinical trial applications for ATG-201 in China and Australia.

Stories mentioning Dr. Jay Mei 2

Biotech pharma Positive 7

UCB and Antengene Ink $1.1B Deal for CD19 Bispecific in Autoimmune Pivot

Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.

2 sources